Abstract
Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells
Proceedings in obstetrics and gynecology, Vol.2(1), pp.1-2
07/13/2011
DOI: 10.17077/2154-4751.1103
Abstract
Dysregulation of mammalian target of rapamycin (mTOR) signaling has been found in many human tumors, including endometrial cancer, and mTOR inhibitors have been utilized in clinical trials as targeted therapies with only limited success. Herein we identify a viable treatment alternative that overcomes temsirolimus-induced AKT phosphorylation in endometrial cancer. Our data suggest temsirolimus and BEZ235 inhibit different components of the AKT/mTOR signaling pathway to accomplish synergistic pathway inhibition, which is necessary for therapeutic efficacy to abrogate the increased signaling through AKT that occurs with mTOR inhibition alone
Details
- Title: Subtitle
- Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells
- Creators
- Shujie Yang - University of IowaXue Xiao - University of IowaXiangbing Meng - University of IowaKimberly K Leslie - University of Iowa
- Resource Type
- Abstract
- Publication Details
- Proceedings in obstetrics and gynecology, Vol.2(1), pp.1-2
- DOI
- 10.17077/2154-4751.1103
- ISSN
- 2154-4751
- eISSN
- 2154-4751
- Language
- English
- Date published
- 07/13/2011
- Academic Unit
- Pathology; Obstetrics and Gynecology
- Record Identifier
- 9984201122302771
Metrics
17 Record Views